Literature DB >> 25556900

Generation of tumor-specific cytotoxic T-lymphocytes from the peripheral blood of colorectal cancer patients for adoptive T-cell transfer.

Silvia Carluccio1, Serena Delbue, Lucia Signorini, Elisabetta Setola, Anna Bagliani, Alberto Della Valle, Andrea Galli, Pasquale Ferrante, Marco Bregni.   

Abstract

This study designs a strategy for an adoptive cellular therapy (ACT) protocol based on the ex-vivo selection of autologous peripheral blood-derived CD8-enriched T-cells, stimulated with dendritic cells (DCs) that had been pulsed with apoptotic tumor cells to generate cytotoxic T lymphocytes (CTLs) with anti-tumor activity. Seventy-eight colorectal cancer (CRC) patients were enrolled in this study. Tumor tissues and peripheral blood (PB) were obtained at surgery. Tissues were mechanically dissociated and cultured to obtain a primary tumor cell line from each patient. DCs were derived from peripheral blood mononuclear cells (PBMCs) using magnetic positive selection of CD14+ monocytes. Anti-tumor CTLs were elicited in co-/micro-cultures using DCs as antigen-presenting cells, autologous apoptotic tumor cells as a source of antigens, and CD8+ T lymphocytes as effectors. Interferon-γ (IFN-γ) secretion was assessed by ELISpot assays to evaluate the activation of the CTLs against the autologous tumor cells. Primary tumor cell lines were obtained from 20 of 78 patients (25.6%). DCs were generated from 26 patients, and of them, corresponding tumor cell lines were derived from six patients. ELISpot results showed that significant IFN-γ secretion was detected after different numbers of stimulations for two patients, whereas weak secretion was observed for three patients. Despite difficulties due to contamination of several primary tumor cell lines with gut intestinal flora, the results suggest that the generation of tumor-specific CTLs is feasible from patients with CRC, and could be useful for supporting an ACT approach in CRC.
© 2015 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2015        PMID: 25556900     DOI: 10.1002/jcp.24886

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  9 in total

1.  TCR sequencing analysis of cancer tissues and tumor draining lymph nodes in colorectal cancer patients.

Authors:  Tatsuo Matsuda; Eisaku Miyauchi; Yu-Wen Hsu; Satoshi Nagayama; Kazuma Kiyotani; Makda Zewde; Jae-Hyun Park; Taigo Kato; Makiko Harada; Shimpei Matsui; Masashi Ueno; Kazumasa Fukuda; Nobuaki Suzuki; Shoichi Hazama; Hiroaki Nagano; Hiroya Takeuchi; Wickii T Vigneswaran; Yuko Kitagawa; Yusuke Nakamura
Journal:  Oncoimmunology       Date:  2019-03-22       Impact factor: 8.110

Review 2.  T Cell Genesis: In Vitro Veritas Est?

Authors:  Patrick M Brauer; Jastaranpreet Singh; Sintia Xhiku; Juan Carlos Zúñiga-Pflücker
Journal:  Trends Immunol       Date:  2016-10-24       Impact factor: 16.687

Review 3.  The generation and application of antigen-specific T cell therapies for cancer and viral-associated disease.

Authors:  Amy B Hont; Allison B Powell; Danielle K Sohai; Izabella K Valdez; Maja Stanojevic; Ashley E Geiger; Kajal Chaudhary; Ehsan Dowlati; Catherine M Bollard; Conrad Russell Y Cruz
Journal:  Mol Ther       Date:  2022-02-09       Impact factor: 12.910

4.  Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses.

Authors:  Valerie Chew; Liyun Lai; Lu Pan; Chun Jye Lim; Juntao Li; Raymond Ong; Camillus Chua; Jing Yao Leong; Kiat Hon Lim; Han Chong Toh; Ser Yee Lee; Chung Yip Chan; Brian K P Goh; Alexander Chung; Pierce K H Chow; Salvatore Albani
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-03       Impact factor: 11.205

Review 5.  Strategy to targeting the immune resistance and novel therapy in colorectal cancer.

Authors:  Wang Gang; Jun-Jie Wang; Rui Guan; Sun Yan; Feng Shi; Jia-Yan Zhang; Zi-Meng Li; Jing Gao; Xing-Li Fu
Journal:  Cancer Med       Date:  2018-04-15       Impact factor: 4.452

6.  Cytokine-Induced Killer (CIK) Cells, In Vitro Expanded under Good Manufacturing Process (GMP) Conditions, Remain Stable over Time after Cryopreservation.

Authors:  Katia Mareschi; Aloe Adamini; Sara Castiglia; Deborah Rustichelli; Laura Castello; Alessandra Mandese; Marco Leone; Giuseppe Pinnetta; Giulia Mesiano; Ivana Ferrero; Franca Fagioli
Journal:  Pharmaceuticals (Basel)       Date:  2020-05-12

7.  Cytokines induced killer cells produced in good manufacturing practices conditions: identification of the most advantageous and safest expansion method in terms of viability, cellular growth and identity.

Authors:  Sara Castiglia; Aloe Adamini; Deborah Rustichelli; Laura Castello; Katia Mareschi; Giuseppe Pinnetta; Marco Leone; Alessandra Mandese; Ivana Ferrero; Giulia Mesiano; Franca Fagioli
Journal:  J Transl Med       Date:  2018-08-29       Impact factor: 5.531

Review 8.  Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells.

Authors:  Cristina Aparicio; Marina Belver; Lucía Enríquez; Francisco Espeso; Lucía Núñez; Ana Sánchez; Miguel Ángel de la Fuente; Margarita González-Vallinas
Journal:  Int J Mol Sci       Date:  2021-10-29       Impact factor: 5.923

9.  Disappearance of bone metastases in chemotherapy-resistant gastric cancer treated with antigen peptide-pulsed dendritic cell-activated cytotoxic T lymphocyte immunotherapy: A case report.

Authors:  Juan Du; Jia Wei; Yang Yang; Shu Su; Jie Shao; Fangjun Chen; Fanyan Meng; Zhengyun Zou; Baorui Liu
Journal:  Oncol Lett       Date:  2018-05-22       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.